Drugs / CN1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04418141 | Jul 2020 → Oct 2021 | lymphoma | Curon Biopharmaceutical (Australia) Co Pty Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04880564 | Jul 2021 → Aug 2022 | lymphoma | Curon Biopharmaceutical (Australia) Co Pty Ltd | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CN1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04880564 ↗ |
| Action | Activate | “CN1 could promote T cell activation and cytokine secretion” NCT04418141 ↗ |
| Route | Intravenous | “Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks).” NCT04418141 ↗ |